The Procter & Gamble PG

Reference table

1. What the business actually is

Five reportable segments plus Corporate. The FY2026 figures below come from the 10-K filed 2026-08-04, not from the vendor payload, because the vendor has no fiscal-2026 segment row at all (Section 8).

The segment sales figures sum to $87.019B against reported revenue of $87.032B — a $13M rounding difference from the filing's presentation to one decimal place. The table is clean.

Read the "Change" column. Every operating segment earned less than it did a year earlier. Beauty, the fastest-growing segment at +7% net sales and +5% organic, still saw net earnings fall 2% because its net earnings margin declined 140 basis points. Fabric & Home Care, the largest, fell 4% on a 110-basis-point margin decline. This is a company-wide margin event, not a segment-specific problem, and it is why the growth score is a 3.

Market share, from the same filing — the most concrete forward warning in the document:

Nine categories lost share; four gained; two were unchanged. The filing attributes most of the losses to "competitive activity" — its own word — in North America and Greater China specifically.

Geography. The vendor supplies only a US versus non-US split, rounded to the nearest $100 million, and has no fiscal-2026 row: FY2025 was United States $41.6B and non-US $42.7B, a roughly even split. The filing's segment commentary works at the regional level (North America, Europe, Latin America, Greater China, Asia Pacific, India/Middle East/Africa) and the recurring pattern is instructive: growth in Latin America, Europe, Greater China and IMEA, attributed to innovation and market growth; declines in North America, attributed to competitive activity and market contraction. For a company with roughly half its sales in the United States, that is the wrong way round.

Headcount. The 10-K states "approximately 104,000 employees, a decrease of 4% versus the prior year due to the ongoing restructuring program." The vendor profile says 109,000. The filing wins; we use 104,000.

Leadership. The 10-K is signed by Shailesh Jejurikar as Chairman, President and Chief Executive Officer, and Andre Schulten as Chief Financial Officer. The filing notes Mr Jejurikar "previously served as Chief Operating Officer (2021-2025) and Chief Executive Officer — Fabric and Home Care (2019-2021)." This is the first annual report under a new chief executive, promoted from within — a fact worth registering when assessing whether the cost programme will be joined by portfolio change.

2. The growth decomposition — the single most important paragraph in the filing

> "Net sales increased 3% to $87.0 billion in fiscal 2026 driven by favorable foreign exchange of 2% and pricing of 1%. Unit volume and mix were unchanged versus the prior year." — FY2026 10-K, MD&A

Procter & Gamble sold no more product in fiscal 2026 than in fiscal 2025. The entire revenue increase came from currency translation and price.

> "Organic sales, which exclude the impact of acquisitions and divestitures and foreign exchange, increased 1%. Organic sales increased mid-single digits in Beauty and low single digits in Health Care, Grooming and Fabric & Home Care. Organic sales declined low single digits in Baby, Feminine & Family Care."

Against management's own published long-term objectives, disclosed in the same document:

Two of three long-term objectives missed, and the one met is the cash-conversion metric — which is the easiest to hit when you are not growing, because growth consumes working capital. This is stated not as a criticism of management but as the honest reading of a document management published this morning.

3. Margins — a 760-basis-point deterioration across four quarters

Annual:

Quarterly, fiscal 2026 — the sequence that matters:

Operating margin fell in every quarter of the fiscal year, from 26.2% to 18.6% — 760 basis points. Revenue also declined sequentially in each of the last three quarters. Fourth-quarter GAAP diluted EPS of $1.26 was 14.9% below the $1.48 of the year-earlier quarter, and fourth-quarter revenue of $21.203B missed the $21.382B consensus in earn_cal. That is the most recent data point available and it is the weakest one.

The 10-K supplies the full gross-margin bridge, which is the most useful table in the document:

The productivity programme is working — 180 basis points of manufacturing savings is a large number — and it was still outrun. Unfavourable product mix alone cost 120 basis points, which is the arithmetic signature of consumers trading down.

On the cost line, the filing states: "Total SG&A increased 6% to $23.9 billion and increased 60 basis points to 27.5% as a percentage of net sales due primarily to an increase in marketing spending." Marketing spending rose 80 basis points as a share of sales; overhead costs were unchanged as "wage inflation headwinds and restructuring spending were offset by productivity savings"; and productivity delivered a further 160 basis points of SG&A benefit. P&G is spending more on marketing while losing share in nine categories — that combination is the definition of an expensive defence.

The conclusion in the filing's own words: "Operating income decreased $703 million, or 3%, to $19.7 billion... The operating margin decreased 160 basis points to 22.7% due primarily to the decrease in gross margin and increase in marketing spending."

Why net earnings still rose slightly. Net earnings increased $79 million to $16.1 billion, and the filing explains that this was "as the decrease in operating income was offset by higher non-operating restructuring charges in the prior year, primarily driven by the non-cash charge for accumulated foreign currency translation losses due to the substantial liquidation of operations in Argentina." Reported earnings grew only because the prior year contained an $801 million after-tax charge that did not repeat. The operating business earned less.

4. Two earnings numbers, and the balance sheet

Core versus GAAP. The 10-K states: "Diluted EPS increased 2% to $6.62 due to an increase in net earnings and a reduction in shares outstanding. Core EPS, which excludes the gain from the dissolution of the Glad joint venture business and incremental restructuring charges, increased 1% to $6.89."

The vendor payload carries both bases without labelling either — the same trap seen elsewhere in this batch. inc_a/inc_q are GAAP ($1.95 + $1.78 + $1.63 + $1.26 = $6.62); earn_cal is core ($1.99 + $1.88 + $1.59 + $1.43 = $6.89). The reconciliation is exact and the filing settles it. Consensus estimates are on the core basis: FY2026 epsAvg was $6.875 against a core actual of $6.89 — a fractional beat, and evidence that the estimate block is core, not GAAP. All forward multiples in this dive therefore run on the core basis.

Balance sheet, FY2026 (2026-06-30):

• Cash and equivalents $9.942B (no short-term investments) · total debt $34.138B ($11.296B short-term, $22.842B long-term) · net debt $24.196B
• Total assets $126.521B · goodwill $41.276B · intangibles $21.444B · property, plant and equipment $25.360B · inventory $8.170B
• Total liabilities $72.210B · total equity $54.311B (minority interest $230M) · retained earnings $135.852B
• Book value per share $22.42 → price to book 6.60x; tangible book value per share −$3.47 → tangibleAssetValueTTM is −$8.409B
• Current ratio 0.677 · working capital −$12.486B · debt to equity 0.629 · financial leverage 2.33x · interest coverage 22.5x

This is the one balance sheet in the batch where the vendor's enterprise-value arithmetic is exactly right. Market cap $351.874B + total debt $34.138B − cash $9.942B = $376.070B, which is precisely km_ttm.enterpriseValueTTM. A 0.0% residual — we verified it and it holds.

But two things must be said about what the balance sheet means. First, tangible book value is negative: $62.720B of goodwill and intangible assets exceeds $54.311B of total equity, so priceToBookRatioTTM of 6.60x and priceToFairValueTTM of 6.60x are multiples of an accounting residual made entirely of acquired brand value, and are rejected as valuation inputs. Second, the risk that creates is real and has precedent: the 10-K recalls that in fiscal 2024 P&G "recorded a $1.3 billion before tax ($1.0 billion after tax) non-cash impairment charge on an indefinite-lived intangible asset acquired as part of the Company's 2005 acquisition of The Gillette Company", driven by a higher discount rate and currency weakness. Brand intangibles of $21.444B sit on the books and are re-tested annually against discount rates.

Negative working capital of $12.486B and a current ratio of 0.677 are features, not defects, for a consumer-products company — days of payables outstanding are 137.3 against 68.8 days of inventory and 25.4 days of receivables, producing a cash conversion cycle of −43.1 days. P&G is financed by its suppliers, which is exactly how a dominant retailer-facing manufacturer should look.

The restructuring, from the filing: "In June 2025, the Company announced a portfolio and productivity plan... The Company expects to incur approximately $1.5 to $2.0 billion in before-tax restructuring costs over a two-year period... The Company incurred over half of the costs under this plan in fiscal 2026, with the remainder expected in fiscal 2027." The programme "include[s] a plan for a reduction of up to 7,000 non-manufacturing overhead personnel by the end of fiscal 2027", with charges "funded by and included within Corporate for segment reporting."

5. Cash flow — the part of the story that is unambiguously good

Operating cash flow of $20.322 billion was a record and rose 14% year over year. The filing reports adjusted free cash flow of $15.8 billion, up 8%, with adjusted free-cash-flow productivity of 100% — meaning P&G converted every dollar of adjusted net earnings into a dollar of free cash — against a management target of 90% or greater. "Net financing activities used $14.5 billion of cash in 2026, mainly due to dividends to shareholders and treasury stock purchases."

The dividend is the asset. Per the 10-K: "P&G has been paying a dividend for 136 consecutive years since its incorporation in 1890 and has increased its dividend for 70 consecutive years since 1956." The trailing rate is $4.2906 per share, a 2.90% yield, costing $10.232 billion a year — covered 1.54 times by adjusted free cash flow and representing a 62.3% payout of core EPS (63.8% of GAAP). Capital expenditure at 5.1% of revenue leaves ample room.

Buybacks are steady but modest: $5.028B in fiscal 2026, reducing the diluted share count from 2.454B to 2.422B — a 1.3% reduction. Over three years the count has fallen from 2.472B, roughly 1.0% a year. Total shareholder yield is therefore about 4.2% (2.90% dividend plus ~1.3% net buyback), which is the highest in this batch and the core of the ownership case.

6. Valuation — priced in or room?

At $148.02 (market cap $351.9B):

Peer context. The vendor peer set is genuinely relevant for once: Colgate-Palmolive ($74.0B), Kimberly-Clark ($37.0B), Clorox ($12.7B), Unilever ($138.1B), Coca-Cola ($372.4B), Philip Morris ($291.3B), Kenvue ($37.5B), Edgewell ($1.3B) and Spectrum Brands ($2.1B) are all consumer staples; Costco ($420.4B) is a retailer rather than a manufacturer and is the odd one out. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn. The observation that stands alone: at $351.9B P&G is the largest pure household and personal-products company in its own comparison set by a factor of more than two.

The vendor's scoring model rates P&G B+ with an overall score of 3, with return-on-equity and return-on-assets sub-scores of 5, a discounted-cash-flow sub-score of 4 (the second-highest in this batch) and a price-to-book sub-score of 1 — the last of which we disregard, since tangible book is negative and the metric is meaningless here.

6a. What today's price assumes (the inversion)

At $148.02 — 21.2x FY2027 consensus core EPS of $6.998 — the price embeds roughly the following falsifiable claims:

• Organic sales growth recovers from 1% toward 2-3% and volume growth returns from zero. (Consensus-derived: revenue of $88.690B FY2027E on 15 analysts and $91.212B FY2028E on 17, i.e. +1.9% and +2.8% — and note that consensus revenue growth is below the reported 3.3% of fiscal 2026, which itself was two-thirds currency.)
• Core EPS reaches ~$7.40 by fiscal 2028, i.e. +7.4% over two years from $6.89. (Consensus-derived, 12 analysts.) That requires the FY2028 growth rate of 5.8% that consensus models, against the 1% actually delivered in fiscal 2026.
• Operating margin stabilises near 22-23% and reverses the four-quarter decline from 26.2% to 18.6%. (Our number, derived from the quarterly series.) This is the most fragile assumption in the price. Every element of the consensus earnings path requires it, and the most recent quarter is the worst one.
• The market keeps paying ~21x forward for 2-3% revenue growth, i.e. no de-rating despite share losses in nine of fifteen disclosed categories. (Our reading.) For context, that is a similar forward multiple to a mega-cap software franchise growing revenue 17% elsewhere in this batch — the defensive premium is doing a great deal of work.
• The restructuring delivers. (Half-weighted management framing, per house rule: the $1.5-2.0B programme and 7,000-role reduction are company statements about a future cost structure, and the fiscal 2027 earnings estimate implicitly banks them.)

6b. The return bridge (why the multiple moves)

Expected return over 12-24 months decomposes as: core EPS growth (+1.6% in FY2027, +5.8% in FY2028 on consensus) + multiple drift (we assume approximately FLAT, 21.2x to ~22x) + shareholder yield (~4.2%: a 2.90% dividend plus ~1.3% of net buyback).

We assume the multiple essentially holds, and we should be explicit that this is the least interesting return bridge in the batch — which is itself the point. There is no re-rating case to make: a business growing organic sales 1%, growing volume 0%, losing share in most categories and reporting lower earnings in all five segments does not obviously deserve to be paid more than 21x. Nor is there a strong compression case while the dividend record is intact and the balance sheet is sound, because the yield puts a floor under the price — at $126 the yield would be 3.4%, which is where income buyers historically appear.

Almost none of the expected return is re-rating, and unusually, almost none is earnings growth either. Most of it is the dividend. From $148.02, at an unchanged 21.2x and consensus FY2027 core EPS of $6.998, the price is $148 — flat. The base case of $155 implies 22.1x, roughly one turn of expansion, and delivers +4.7%. Add the 2.90% yield and the total expected return is approximately 7.6% over twelve months. That is a reasonable outcome for a 0.38-beta asset and a poor one against a market that returned 24.3% in the last twelve months.

The bull case at $182 requires 26.0x FY2027E, roughly the multiple P&G commanded in its better years, and it needs organic growth to re-accelerate and margins to recover simultaneously. On today's evidence that is the fragile leg and it is not the central expectation.

6c. Variant perception (where we differ, what would surprise)

• We differ from the headline narrative on what "3% sales growth" means, and the filing is our authority. Reported net sales rose 3.3% to $87.032B, which reads as an acceleration from fiscal 2025's +0.3%. The 10-K attributes it to "favorable foreign exchange of 2% and pricing of 1%" with "unit volume and mix unchanged." Organic growth was 1% and volume growth was zero. Currency is not a business improvement and it reverses. Watchable number: organic sales growth and its volume component at each quarterly print.
• We differ on how the segment results should be read, because we have not seen the "all five declined" framing anywhere. Beauty grew net sales 7% and organic sales 5% — a genuinely good result — and its net earnings still fell 2%. Fabric & Home Care, 34.8% of the company, saw earnings fall 4%. The margin problem is universal, and a universal problem is structural until proven cyclical. Watchable number: segment net earnings at the fiscal-2027 half-year, where two of five turning positive would materially change the assessment.
• We differ from the vendor's own metrics on the balance sheet's meaning. priceToBookRatioTTM of 6.60x and priceToFairValueTTM of 6.60x are computed on an equity base of $54.311B that contains $62.720B of goodwill and intangibles — tangible book value per share is negative $3.47. We reject both metrics. The relevant balance-sheet facts are 22.5x interest coverage, a −43.1-day cash conversion cycle and $15.8B of adjusted free cash flow, all of which are excellent.
• We have essentially NO informational edge here, and we say so plainly. Two knowledge-base claims name this company across 51,928 records, both over three years old, neither a valuation call. Our base fair value of $155 sits 2.2% below the street consensus of $158.56 and inside the published target range of $142-$172. We are not differing from the crowd; we are agreeing with it slightly more pessimistically, on the strength of a filing published this morning. Per the house rule, a no-edge name defaults toward Hold, and that is exactly where this lands.
• Positive surprise that would force a re-rate: volume growth returning to positive with organic sales above 3%, or operating margin recovering above 23% in the fiscal 2027 first half, or the restructuring delivering a visible step-down in the cost base. A larger-than-usual dividend increase in April 2027 would also signal management confidence. Watchable numbers: organic volume; quarterly operating margin against 18.6%.
• Negative surprise that would break the thesis: organic sales turning negative, continued share loss in Fabric & Home Care (34.8% of sales, currently unchanged at segment level but −0.4 points in fabric care), a brand intangible impairment of the kind taken on the razor business in fiscal 2024, or a dividend increase of less than 2% — which after 70 consecutive years would be read as a signal about cash confidence far beyond its arithmetic. Watchable numbers: organic sales by segment; the annual dividend declaration.

Synthos fair values

All three anchors are multiples of FY2027 consensus core EPS of $6.998 (14 analysts), cross-checked against FY2028E of $7.404 (12 analysts).

• Bear ~$126 — 18.0x FY2027E. Cross-check: 17.0x FY2028E; a 3.41% dividend yield, which is where income buyers have historically appeared. The scenario: organic growth turns negative, the four-quarter margin slide continues into fiscal 2027, share losses accelerate, and the market re-rates P&G as a low-growth annuity. Note this is only 8.7% below the 52-week low of $138.04. −14.9%.
• Base ~$155 — 22.1x FY2027E. Cross-check: 20.9x FY2028E; a 2.77% yield. Sits 2.2% below the street consensus of $158.56 and 4.3% below the median of $162. The scenario: margins stabilise, organic growth stays in the 1-3% band, the restructuring delivers as promised, and the dividend does the work. +4.7%, plus a 2.90% yield for a total of roughly +7.6%.
• Bull ~$182 — 26.0x FY2027E. Cross-check: 24.6x FY2028E; a 2.36% yield; above the street high of $172. The scenario: volume growth returns, the productivity programme's 180 basis points of manufacturing savings flow through to margin rather than being consumed by mix, and P&G re-rates toward its historical premium. +22.9%.

Base is 4.7% above spot; asymmetry roughly 1.5:1 to the upside (15% down, 23% up). The dividend is the return. That is a Hold.

7. Knowledge base — two claims, both stale, and what that means

Tracked knowledge-base claims naming Procter & Gamble: 2 raw hits, 2 entity-level, 0 discarded. Search covered Procter & Gamble, Procter and Gamble and P&G across all 51,928 knowledge-base records. This is the thinnest lane in this batch by a wide margin — for comparison, another name covered today returned 402 entity-level claims from the same corpus.

Both claims are bullish, both are more than three years old, and neither is about the equity:

> 2023-05-06 · business_breakdowns · bullish · conviction 80 · entities: Procter and Gamble, Johnson & Johnson, Febreze

> "Mass-market consumer success comes from engineering habit formation and tying products to a repeatable ritual, as legacy CPG giants do."

> 2022-04-13 · macro_trading_floor · bullish · conviction 70 · entities: Consumer staples, Walmart, Procter & Gamble, Tesla, Amazon

> "Long consumer staples (XLP/Walmart/P&G) vs short consumer discretionary (Tesla/Amazon): weakening demand plus food inflation shifts spending to necessities."

What this lane establishes, honestly.

The first claim is a principle, not a call: it uses P&G as an illustration of how consumer packaged-goods economics work, which is analytically useful and carries no view on price. The second is a four-year-old macro rotation trade whose thesis (food inflation driving spending toward necessities) has long since played out and reversed.

Neither claim references a price, a multiple, a segment, a competitive position or a forecast. Neither has been refreshed in over three years. There is no negative claim either — but the absence of disagreement in a sample of two is not evidence of consensus.

The correct conclusion is that we have no expert underwriting on this name whatsoever, and we treat that as a verdict input rather than a gap to be papered over. The house standing rule is that a name with no variant perception defaults toward Hold or Watch. Our fair value of $155 sits below the street's $158.56 and inside its $142-$172 range; our disagreement with consensus is 2.2% and is driven entirely by a filing that was published this morning and that every analyst will have read by Friday. That is not an edge. It is a slightly earlier reading of a public document.

Conviction rating: None (quantitative only). Two claims, two sources, zero recent, zero valuation-relevant, zero discarded.

8. Data integrity — what we rejected from the vendor file and why

Eight items. Three are direct filing-versus-vendor contradictions, and in every one the filing wins. This file has more internal corruption than most in this batch.

1. FILING OVERRIDES VENDOR — there is no fiscal-2026 segment data in the vendor file at all. seg_prod stops at FY2025 and seg_geo stops at FY2025. All fiscal-2026 segment revenue and segment net earnings in this dive come from the 10-K filed 2026-08-04, and are reported to the filing's one-decimal precision. The vendor's FY2025 labels are also mangled ("Baby, Feminine and Family Care Segment Member", "Fabric Care And Home Care Segment Member") and the FY2025 row omits the Corporate segment that is present in FY2024 and earlier — the five FY2025 lines sum to $83.489B against reported revenue of $84.284B, a $795M gap that is the missing Corporate line. Corrected against the filing.

2. FILING OVERRIDES VENDOR — the earnings basis is ambiguous and unlabelled. inc_a/inc_q carry GAAP diluted EPS ($1.95 + $1.78 + $1.63 + $1.26 = $6.62); earn_cal carries core EPS ($1.99 + $1.88 + $1.59 + $1.43 = $6.89). The 10-K settles it: "Diluted EPS increased 2% to $6.62... Core EPS, which excludes the gain from the dissolution of the Glad joint venture business and incremental restructuring charges, increased 1% to $6.89." We use core EPS of $6.89 for all valuation work, because consensus (est FY2026 epsAvg $6.875) is built on that basis, and we report both.

3. FILING OVERRIDES VENDOR — headcount. Profile: 109,000. 10-K: "approximately 104,000 employees, a decrease of 4% versus the prior year due to the ongoing restructuring program." We use 104,000.

4. Income-statement depreciation and amortisation is CORRUPT for fiscal 2026 — all EBITDA metrics REJECTED. inc_a FY2026 reports depreciationAndAmortization of $0.00 while cf_a FY2026 reports $3.160B; and inc_q for the quarter ended 2026-06-30 reports D&A of negative $2.348B, which is not a possible value. The consequence is visible in the ratio block: ebitdaMarginTTM (24.421%) is IDENTICAL to ebitMarginTTM (24.421%) to five decimal places, because the vendor is adding zero depreciation. The inc_a FY2026 ebitda figure of $21.254B is also irreconcilable with operating income of $19.748B plus D&A of zero. evToEBITDATTM (17.69x), netDebtToEBITDATTM (1.138x), enterpriseValueMultipleTTM (17.69x), ebitdaMarginTTM and the FY2026 inc_a EBITDA line are all REJECTED. We use the cash-flow statement's $3.160B where a depreciation figure is needed.

5. est EBITDA is below est EBIT in ALL EIGHT estimate rows — the estimate block's EBITDA/EBIT is systematically corrupt and REJECTED. FY2024 ($22.270B vs $22.389B), FY2025 ($22.352B vs $22.472B), FY2026 ($23.131B vs $23.255B), FY2027 ($23.540B vs $23.666B), FY2028 ($24.210B vs $24.339B), FY2029 ($25.056B vs $25.190B), FY2030 ($25.716B vs $25.853B), FY2031 ($24.993B vs $25.127B). EBITDA cannot be less than EBIT. All EBITDA, EBIT and net-income estimate rows are rejected; forward valuation runs on epsAvg only.

6. Research and development is reported as $0.00 in every year — a known omission, not a fact. researchAndDevelopementToRevenueTTM is 0. P&G unquestionably conducts and discloses research spending; the vendor folds it into selling, general and administrative expenses. We make no R&D-based claim anywhere in this dive and note the gap rather than estimating around it.

7. Balance-sheet sub-categories are not comparable between FY2025 and FY2026. treasuryStock goes from −$138.702B (FY2025) to $0.00 (FY2026); capitalLeaseObligationsCurrent from $255M to $0 and capitalLeaseObligationsNonCurrent from $701M to $0 — the entire lease liability disappears from the vendor's fiscal-2026 sheet; otherCurrentAssets from $2.100B to $0. These are presentation re-mappings rather than economic events. Only totals are used. Note that this also means no lease analysis is possible from the vendor file; the totals ($34.138B of debt, $126.521B of assets) are internally consistent and are what we rely on.

8. The insider file is substantially corrupt and is NOT used. Eight records, all for a single reporting person, every one with a blank transactionType, and — decisively — four records dated in the FUTURE: 2026-09-15, 2026-10-02, 2027-09-13 and 2027-10-01, all filed 2026-07-10. These are option exercisability or expiry dates being written into the transaction-date field. Section 10 reports the defect rather than an analysis.

Not defects, correctly reported and independently verified: km_ttm.enterpriseValueTTM of $376.070B rebuilds exactly from market cap $351.874B + total debt $34.138B − cash $9.942B = $376.070B, a 0.0% residual — the cleanest enterprise-value reconstruction in this batch, and we say so because we flag the failures elsewhere. currentRatioTTM of 0.677 and negative working capital of $12.486B are correct and are features, given a −43.1-day cash conversion cycle. dividendYieldTTM of 2.899% and dividendPerShareTTM of $4.2906 are consistent with the cash-flow dividend payment of $10.232B on 2.422B diluted shares (≈$4.22 per share, the difference being timing and share-count basis).

One minor inconsistency, flagged: quote.price is $148.02 and tech.last is $148.01; quote.yearLow is $137.62 (intraday) against tech.lo52 of $138.04 (closes). We use the technical series' closing figures throughout for consistency and note that the difference is immaterial.

Non-equity tripwire: checked, and worth pausing on. PG has some superficial characteristics of a fixed-income-like instrument — beta 0.38, a stable and rising dividend, and a 52-week range of only $138.04-$167.20 (a 21% band, the narrowest in this batch). But it is unambiguously common equity: average daily volume is 8.7 million shares, the dividend is variable and discretionary (raised for 70 consecutive years, not fixed), the price is nowhere near a par value, and the company files as an operating registrant. Not a preferred, not a baby bond. The tripwire is noted precisely because this is the name in the batch most likely to trip a naive screen.

9. Technicals — the most neutral chart in the batch

• Price $148.02, up 2.10% on the day — a notably large single-day move for a 0.38-beta consumer staple, and one that coincided with the filing of the annual report. Volume of 5.3M against an 8.7M average, so the move came on below-average volume, which argues against reading much into it.
• Sitting on both moving averages, almost exactly. The 50-DMA is $147.48 and the 200-DMA is $148.03; the closing price on the technical series is $148.01. The stock is 0.4% above its fifty-day average and 0.01% below its two-hundred-day average. It is difficult to construct a more precisely neutral position.
• RSI 49.90 — within a tenth of the neutral 50. MACD −0.56, marginally negative.
• −11.5% from the 52-week closing high of $167.20; +7.2% above the low of $138.04. Maximum drawdown from peak over the trailing year is −17.6%, deeper than the current 11.5%, indicating an intra-year trough below the current level.
• Relative performance, and it is uniformly poor: 12-month −1.75% against SPY +24.26% and QQQ +30.80% (a 26-to-33 point deficit); 6-month −3.38% against SPY +11.09%; 3-month +3.20% against SPY +7.59%. There is no horizon on which this stock has kept pace.
• Practical read. The chart offers no information. A price on both moving averages with an RSI of 50 is the market saying it has no view, which is consistent with a covering street split 28 buy / 24 hold / 1 sell — the weakest buy ratio in this batch. There is neither a technical reason to buy nor one to sell. For an existing holder, the 52-week low of $138.04 is 6.7% below and would take the yield to 3.11%; that is the level at which the income case becomes genuinely compelling and at which adding would be defensible. At $148.02, the honest technical verdict matches the fundamental one: nothing to do.

10. Insiders — the file is corrupt and we will not pretend to read it

The insider records for PG in this payload cannot be used, and the reason is worth stating precisely rather than presenting a table that looks like analysis.

All eight records relate to a single reporting person (Juliana Monteiro Santos de Azevedo, Chief Executive Officer — Grooming), all were filed 2026-07-10, and every record has a blank transactionType field. More seriously, four of the eight carry transaction dates in the future: 2026-09-15, 2026-10-02, 2027-09-13 and 2027-10-01. A transaction cannot occur after the date it was reported. These are almost certainly option exercisability or expiration dates — the associated security is described as "Stock Option (Right to Buy)" with strike-like prices of $128.51, $145.19, $153.47, $173.04 and $174.08 — being written into the transaction-date column.

What can be said, cautiously. The records show one officer holding 19,362 shares directly and 331 indirectly, plus option positions at strikes ranging from $128.51 to $174.08. No open-market purchase or sale by any insider appears in this file. That is the entire content.

What cannot be said. Nothing about insider sentiment, accumulation, distribution or conviction. A single officer's option schedule, mis-parsed, is not an insider signal, and presenting it as one would be exactly the sort of smoothing-over this house forbids. We report the defect and draw no conclusion. (Logged as item 8 in Section 8.)

11. Verdict, kill-criteria and flip conditions

Hold.

Procter & Gamble is a superb defensive asset having a genuinely poor operating year, priced as though the poor year is temporary. It might be. There is not enough margin of safety in the price to bet meaningfully either way.

What is genuinely excellent, and none of it is in doubt. 136 consecutive years of dividend payments and 70 consecutive years of increases — a record that exists nowhere else in this batch and almost nowhere in the market. A 2.90% yield costing $10.232 billion against $15.8 billion of adjusted free cash flow, giving 1.54x cover at a 62.3% core payout. 100% adjusted free-cash-flow productivity against a 90% target. Operating cash flow at a record $20.322 billion, up 14%. Return on equity of 29.8%, return on invested capital of 15.8%, interest coverage of 22.5x, capital expenditure of only 5.1% of revenue, a −43.1-day cash conversion cycle, and a beta of 0.38 — the lowest here.

What you are accepting, in the words of a filing published this morning. Net earnings declined in all five operating segments. Net sales rose 3% but "unit volume and mix were unchanged" and organic sales grew 1%. Operating income fell $703 million or 3%; operating margin fell 160 basis points to 22.7%, with a quarterly path of 26.2% → 24.2% → 21.5% → 18.6%. Fourth-quarter GAAP EPS of $1.26 was 14.9% below the prior year and revenue missed consensus. Market share fell in nine of fifteen disclosed categories, with the filing attributing the losses to "competitive activity" in North America and Greater China. Core EPS grew 1% against a stated objective of mid-to-high single digits — management missed two of its own three long-term goals. Up to 7,000 overhead roles are being removed. And there is no expert conviction lane at all: two knowledge-base claims, both over three years old, neither a valuation call.

The arithmetic. Base fair value $155 against $148.02 is +4.7%, plus a 2.90% dividend — roughly 7.6% of expected total return over twelve months, against a 14.9% bear case. Our base sits 2.2% below the street consensus of $158.56, which is to say we have no variant perception, and the house default for a no-edge name is Hold.

Pre-registered KILL criteria — what would move this to Avoid:

• Organic sales growth turning negative at company level. It was +1% in fiscal 2026 and already negative in Baby, Feminine & Family Care.
• Operating margin below 18% for two consecutive quarters. The fourth quarter of fiscal 2026 printed 18.6%.
• Continued share loss in Fabric & Home Care, which is 34.8% of sales and where segment share was unchanged but fabric care fell 0.4 points — this is the segment the company cannot afford to lose.
• A brand intangible impairment of the kind taken in fiscal 2024 on the razor business ($1.3B pre-tax). $21.444B of intangibles sit on a balance sheet with negative tangible book value.
• A dividend increase below ~2% in April 2027. After 70 consecutive years, the size of the increase is management's clearest unhedged statement about confidence, and a token rise would say more than any guidance.
• Adjusted free-cash-flow productivity falling below 90%, the company's own stated floor.

Pre-registered FLIP TO BUY (upsize) criteria:

• A price near $138 (the 52-week low), giving a 3.11% yield — the level at which the income case becomes compelling on its own and at which we would add regardless of the growth picture.
• Positive unit volume growth with organic sales above 3%. Volume was zero in fiscal 2026; its return would be the single cleanest signal that the franchise is intact.
• Operating margin recovering above 23% in the fiscal 2027 first half, reversing the four-quarter slide.
• Two or more segments returning to net earnings growth.
• Evidence that the restructuring has delivered a structurally lower cost base — specifically, overhead costs falling as a percentage of net sales, which were merely "unchanged" in fiscal 2026 despite the programme.

Where PG fits in the Synthos Framework Portfolio. The low-beta defensive income sleeve, as a 1-2% holding for an income mandate and nothing at all for a growth mandate. The justification for the small size: the total expected return of roughly 7.6% is adequate but unexceptional; there is no conviction lane; and the house selection philosophy is explicitly to pick forward next-exponentials rather than trailing compounders — P&G is neither, it is a trailing annuity, and it should be sized as one. If the objective is defensive ballast with an inflation-linked income stream and a 0.38 beta, this is among the best instruments available. If the objective is return, it is not.

Single biggest risk: that 1% organic growth, zero volume growth and falling category share are the new normal rather than a bad year. The filing gives evidence for both readings. For "bad year": Beauty grew organic sales 5%, the productivity programme delivered 180 basis points of manufacturing savings, and the restructuring costs that hurt fiscal 2026 margins are explicitly temporary. For "new normal": share fell in nine of fifteen categories, the losses are concentrated in North America where roughly half the revenue sits, unfavourable product mix cost 120 basis points of gross margin (the signature of consumers trading down), and marketing spending rose 80 basis points while share fell anyway. We do not claim to know which it is, and the price does not pay us enough to guess.

Most fragile assumption in the price: that operating margin stabilises near 22-23%. It ended fiscal 2026 at 18.6% after four consecutive quarterly declines totalling 760 basis points. Every element of the valuation — the 21.2x forward multiple, the consensus core-EPS path to $7.404 in fiscal 2028, the base case of $155, and the dividend's 1.54x cover — assumes that slide arrests in the first half of fiscal 2027. The next print, on 2026-10-23, is the first test.

Provenance & disclosures

• Traceability: only 2 tagged knowledge-base claims name Procter & Gamble across all 51,928 records (2 raw hits, 2 entity-level, 0 discarded; breadth 2 distinct sources; net conviction none). Both are bullish, both predate 2025 (2022-04-13 and 2023-05-06), and neither is a valuation call — one is a general principle about habit formation in consumer packaged goods, the other a 2022 staples-versus-discretionary rotation trade. Searches covered Procter & Gamble, Procter and Gamble and P&G. This dive carries no expert underwriting and the conviction rating is "None (quantitative only)", which is an explicit input to the Hold verdict under the house no-edge default. All quoted claims are verbatim from the stored claim text.
• Data as-of: fundamentals — fiscal year 2026 ended 2026-06-30, 10-K filed 2026-08-04, the same day as this dive; this is the freshest annual report in the batch · estimates 2026-08-04 · prices 2026-08-04 ($148.02 quote / $148.01 technical close; 50-DMA $147.48; 200-DMA $148.03; RSI 49.90) · knowledge-base claims 2026-08-04. Every figure comes from the Synthos vendor data file for PG or from the SEC filings in filings/PG/; no figure comes from memory, recall or external retrieval.
• Filings consulted: 10-K filed 2026-08-04 (FY2026 — the primary source for this dive); 10-Q filed 2026-01-23; 10-Q filed 2026-04-24; 8-K filed 2026-07-29 (the Q4 and full-year earnings release). Note that PG has only four filings in this feed, not the usual six — one 10-Q and two 8-Ks are absent, which is stated as a coverage gap rather than worked around.
• Filing-versus-vendor overrides (three, all resolved in favour of the filing): (1) segment data — the vendor has no fiscal-2026 segment row at all, and its FY2025 row omits the Corporate segment (five lines summing to $83.489B against reported revenue of $84.284B) and uses mangled labels; all FY2026 segment revenue and net earnings come from the 10-K; (2) earnings basis — the vendor carries GAAP EPS ($6.62) in the statement blocks and core EPS ($6.89) in the earnings calendar without labelling either, and the 10-K identifies the difference as the Glad joint-venture dissolution gain and incremental restructuring charges; we use core EPS of $6.89 because consensus is built on it; (3) headcount — vendor 109,000 against the filing's approximately 104,000, down 4%.
• Other data rejections (detailed in Section 8): income-statement depreciation and amortisation is corrupt for fiscal 2026 (annual $0.00 against a cash-flow figure of $3.160B; the June quarter reports negative $2.348B), so ebitdaMarginTTM equals ebitMarginTTM exactly and all EBITDA-derived metrics are rejected (evToEBITDATTM 17.69x, netDebtToEBITDATTM 1.138x, enterpriseValueMultipleTTM 17.69x, and the FY2026 inc_a EBITDA line); est EBITDA is below est EBIT in all eight estimate rows, so every EBITDA/EBIT/net-income estimate row is rejected and forward valuation runs on epsAvg only; research and development is reported as $0.00 in every year (folded into SG&A) and no R&D-based claim is made; FY2026 balance-sheet sub-categories are non-comparable re-mappings (treasury stock −$138.702B → $0.00; capital-lease obligations $956M → $0; other current assets $2.100B → $0), so only totals are used; priceToBookRatioTTM and priceToFairValueTTM (both 6.60x) are rejected because tangible book value per share is negative $3.47; and the insider file is substantially corrupt — all eight records have a blank transaction type and four carry transaction dates in the future — so no insider conclusion is drawn.
• Verified as correct: km_ttm.enterpriseValueTTM of $376.070B rebuilds exactly from market cap plus debt less cash — a 0.0% residual, the cleanest in this batch. currentRatioTTM of 0.677 and negative working capital are correct and are features of a −43.1-day cash conversion cycle.
• Estimate coverage: FY2027 14 analysts on EPS and 15 on revenue — the primary forward anchor; FY2028 12 and 17; FY2029 5 and 13; FY2030 1 and 12; FY2031 2 and 5. No conclusion in this dive rests on the FY2029, FY2030 or FY2031 rows. Note that the FY2031 revenue estimate ($94.163B) is below FY2030's ($96.887B) and the FY2031 EPS estimate ($6.78) is below FY2030's ($7.848) — internally incoherent, and a direct consequence of one- and two-analyst samples.
• Peer note: the vendor peer set is genuinely relevant — Colgate-Palmolive ($74.0B), Kimberly-Clark ($37.0B), Clorox ($12.7B), Unilever ($138.1B), Coca-Cola ($372.4B), Philip Morris ($291.3B), Kenvue ($37.5B), Edgewell ($1.3B), Spectrum Brands ($2.1B) — with Costco ($420.4B) the odd inclusion as a retailer rather than a manufacturer. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn.
• Fair-value caveat: the $126 / $155 / $182 anchors are multiples of FY2027 consensus core EPS of $6.998 (18.0x / 22.1x / 26.0x), cross-checked against FY2028E of $7.404 and against the implied dividend yield at each level (3.41% / 2.77% / 2.36%). Stated arithmetic, not a discounted cash flow. At an unchanged 21.2x the FY2027 consensus implies approximately today's price; the base case requires roughly one turn of expansion and is delivered mostly by the dividend rather than by earnings growth.
• Timing: the fourth quarter of fiscal 2026 was reported 2026-07-29 and the FY2026 10-K filed 2026-08-04 — the day of this dive, which is the primary reason to publish now. The next print is 2026-10-23, 80 days away — no earnings banner applies.
• Accessibility note: all tables are labelled, all emphasis is carried by text rather than colour, and every figure is stated in full rather than encoded in a chart.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.